Breaks Categories: News

TuesdayNov 16, 2021 12:48 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) CEO Featured in Latest Episode of ‘Bell2Bell’ Podcast

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation, was featured in the latest episode of The Bell2Bell Podcast. Among other highlights of the interview, Delic CEO Matt Stang discussed the company’s network of businesses and the impact psychedelic research is having on the treatment of mental health. “We feel that the time is right now. The mental health crisis is sweeping not only this country but the world,” Delic Holdings CEO Matt Stang stated in the interview. “Last year, in America, we had four-times the…

Continue Reading

TuesdayNov 16, 2021 9:30 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Strategic Appointment of World-Renowned Immunologist and Cytokine Expert

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has announced the appointment of Eleanor N. Fish, Ph.D., to its research and clinical advisory board. Dr. Fish is an accomplished researcher in the areas of immunology and inflammatory disorders and a member of the government of Canada’s expert scientific panel to the chief scientific advisor. She brings key expertise to FSD Pharma that will support the continued development of FSD-PEA, the company’s proprietary anti-inflammatory agent, and Lucid-MS, its drug candidate for the treatment of multiple sclerosis.…

Continue Reading

MondayNov 15, 2021 11:02 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q2 Financial Results, Business Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has released its unaudited second-quarter results and announced a conference call to review the report. The report covers the period ended Sept. 30, 2021. Highlights in the report included the company’s announcement of preclinical data for its novel deuterated psilocybin analog, CYB003, for the potential treatment of major depressive disorder and alcohol use disorder. The company has also been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency for its Boston-area research lab and has received FDA approval to proceed with a company-sponsored…

Continue Reading

ThursdayNov 11, 2021 10:01 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) First-Ever Meet Delic Experience Ranks as World’s Largest Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has released information regarding its inaugural Meet Delic event, which was held last week in Las Vegas. The company noted that the event was sold out, with more than 2,500 people in attendance, making the psychedelic edutainment experience and business expo the largest in the world. The event agenda featured 20 hours of talks, panels and discussions presented by more than 60 thought leaders, medical professionals and wellness advocates. The company has already released dates for the next year’s Meet Delic…

Continue Reading

WednesdayNov 10, 2021 12:45 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CMO to Participate in Horizons’ Veterans & Families Forum

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has announced that chief medical officer Dr. Rakesh Jetly will be part of the Horizons' Veterans & Families Forum. The forum is scheduled for Nov. 10, and Jetly will be a panel member for a presentation titled “The State of Care and the Case for Psychedelic Therapy.” The panel will begin at 7:30 p.m. The event is designed specifically for veterans and will be held in NYC at the Judson Memorial Church; a virtual webcast will…

Continue Reading

TuesdayNov 09, 2021 10:38 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release Q2 2021 Financial Results, Host Call

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is planning to release its Q2 2021 financial report on Nov. 15, 2021. The report will cover the period ended Sept. 30, 2021. The company  is also planning on hosting a conference call and webcast the same day, which is scheduled to begin at 4:30 p.m. EST. The call will be hosted by Cybin CEO Doug Drysdale and will provide an overview of the financial results along with relevant business updates. In addition, Drysdale and other team members will answer questions during the call. Those who…

Continue Reading

TuesdayNov 09, 2021 9:57 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Ketamine Wellness Centers Acquisition

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has completed the acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”). The completion firmly establishes Delic as the largest chain of wellness centers that provide ketamine treatments in the United States. Delic now offers access to new medicines and treatments through 12 operational clinics spread across 10 states, including Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, Utah. The company anticipates opening 15 additional clinics in the next 18 months. In addition, Kevin Nicholson, KWC CEO, was appointed chief operating officer at…

Continue Reading

MondayNov 08, 2021 11:00 am

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Demonstrates Numerous Advantages over Oral Psilocybin for Treatment of Mental Health

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive CYB003 pre-clinical findings. According to the update, the findings demonstrate multiple advantages for Cybin’s newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental health care, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Cybin’s CEO Doug Drysdale in the news release. “Cybin has always strived to develop safer and more effective therapies for patients, which…

Continue Reading

MondayNov 08, 2021 10:25 am

PsychedelicNewsBreaks – Wonderland: Miami to Showcase Top Companies, Latest IPOs and Recent Developments in Psychedelics

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting the upcoming Wonderland Miami Conference. The event, designed to provide attendees with insights into some of the top companies, latest IPOs, newest opportunities and most recent developments within the space, is slated to take place on Nov. 8-9, 2021, at Miami’s Adrienne Arsht Center for the Performing Arts. Microdose Psychedelic Insights has announced further details on the event’s agenda. According to the update, speakers will include Robin Carhart-Harris, the…

Continue Reading

ThursdayNov 04, 2021 1:22 pm

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), Provides Studies, Clinical Trials Update

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has released an update on strategic initiatives related to its MINDCURE Research and MINDCURE Technology divisions. According to the company, its synthetic ibogaine efforts, which were announced in March 2021, include the application for two patents and the initiation of production of Good Laboratory Practice (“GLP”) ibogaine leading to the production of Good Manufacturing Practice (“GMP”) ibogaine. The company is on schedule to provide GLP supply to research partners by Q2 2022. The company is in the process of preparing to ship…

Continue Reading